Oncogene-Directed Therapies: Cancer drug discovery and development/ Edited by Janusz Rak.

By:

Rak, Janusz

Material type: Text

9780896039827

Subject(s):

DDC classification:

22 616.994042 RAK

Contents:

I Basic Concepts in Oncogene Research -- 1 Genetic Basis of Cancer Progression -- 2 The Molecular Basis of Chromosomal Instability in Human Cancer Cells -- 3 Signal Transduction Networks: Ras as a Paradigm -- 4 Oncogenic Receptor Tyrosine Kinases -- 5 Ras-Mediated Deregulation of Gene Expression and Contribution to Oncogenesis -- 6 The Interplay Between Tumor Suppressor Genes and Oncogenes in Tumorigenesis -- 7 Genetic Basis of Altered Responsiveness of Cancer Cells to Their Microenvironment -- II. The Functional Impact of Oncogene Expression on Cancer Cellstherapeutic Implications -- 8 Deregulation of Cell Cycle Progression by Oncogenic Transformation -- 9 Oncogenes as Regulators of Cell Survival: The Role of Oncogenes and Tumor Suppressor Genes in the Induction of Resistance to Anoikis and Hypoxia -- 10 Oncogenes and Tumor Angiogenesis -- 11 Oncogenes as Therapeutic Targets to Prevent Metastasis -- 12 The Impact of Oncogenes on Tumor Maintenance -- 13 Primary and Secondary Events in Oncogene-Driven Tumor Development: Lessons from Transgenic Model Systems -- III. Oncogenes as Targets for Anticancer Therapy In Vivo -- 14 Targeting Oncogenes in Hematopoietic Malignancies -- 15 Clinical Evaluation of Agents Targeting Epidermal Growth Factor Receptor (EGFR) in Cancer -- 16 Inhibition of the HER-2/neu Oncogene: A Translational Research Model for the Development of Future Targeted Therapies -- 17 Farnesyltransferase Inhibitors as Anticancer Agents -- 18 Targeting Oncogenic Signaling Pathways in Human Astrocytomas -- 19 Targeting Oncogenes in Pediatric Malignancies -- 20 Inhibiting Signal Transduction as an Approach to Radiosensitizing Tumor Cells -- 21 Oncogenes as Targets for Cancer Vaccines -- 22 Bcl-2 Antisense Oligonucleotides Therapy for Cancer: Targeting the Mitochondria.

Summary: In recent years an entirely new category of anticancer agents has entered the clinic. This class of drugs, the frontrunners of which are Herceptin and Gleevec, are no longer a product of the intuitive and largely empirical explorations that brought about traditional anticancer treatments like chemotherapy. Rather, these new agents have emerged directly from molecular analysis of various cancer-causing genes (oncogenes). In Oncogene-Directed Therapies, prominent investigators and clinicians, several of them pioneers in the field, summarize what is known about oncogenes and oncogenesis-in a balanced blend of fundamental science, basic research, experimental therapeutics, and early clinical experience-and describe how that knowledge can be used to treat the disease. The contributors explain how, why, and under what conditions certain proteins acquire the ability to transform eukaryotic cells, and detail the crucial biological consequences of this oncogenic transformation, particularly for cellular mitogenesis, survival, differentiation, migration, proteolysis, or angiogenic competence. Their articles thoroughly explicate the premises, principles, techniques, and approaches to oncogene targeting in various types of human cancer by using signal transduction inhibitors, immunological targeting methods, and antisense gene therapy. Also included is a review of the results of preclinical and clinical testing of some of today's most advanced therapeutic agents. Unique in perspective and comprehensive in its coverage, Oncogene-Directed Therapies not only integrates for all those engaged in-or simply interested in the cutting-edge of-"the war on cancer" the many remarkable recent achievements in our molecular understanding and treatment of these diseases, but also clarifies what directions future research might optimally take, as well as what significant accomplishments might lie ahead.

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
General Books	CUTN Central Library Medicine, Technology & Management	Non-fiction	616.994042 RAK (Browse shelf(Opens below))	Available		41773

I Basic Concepts in Oncogene Research --
1 Genetic Basis of Cancer Progression --
2 The Molecular Basis of Chromosomal Instability in Human Cancer Cells --
3 Signal Transduction Networks: Ras as a Paradigm --
4 Oncogenic Receptor Tyrosine Kinases --
5 Ras-Mediated Deregulation of Gene Expression and Contribution to Oncogenesis --
6 The Interplay Between Tumor Suppressor Genes and Oncogenes in Tumorigenesis --
7 Genetic Basis of Altered Responsiveness of Cancer Cells to Their Microenvironment --
II. The Functional Impact of Oncogene Expression on Cancer Cellstherapeutic Implications --
8 Deregulation of Cell Cycle Progression by Oncogenic Transformation --
9 Oncogenes as Regulators of Cell Survival: The Role of Oncogenes and Tumor Suppressor Genes in the Induction of Resistance to Anoikis and Hypoxia --
10 Oncogenes and Tumor Angiogenesis --
11 Oncogenes as Therapeutic Targets to Prevent Metastasis --
12 The Impact of Oncogenes on Tumor Maintenance --
13 Primary and Secondary Events in Oncogene-Driven Tumor Development: Lessons from Transgenic Model Systems --
III. Oncogenes as Targets for Anticancer Therapy In Vivo --
14 Targeting Oncogenes in Hematopoietic Malignancies --
15 Clinical Evaluation of Agents Targeting Epidermal Growth Factor Receptor (EGFR) in Cancer --
16 Inhibition of the HER-2/neu Oncogene: A Translational Research Model for the Development of Future Targeted Therapies --
17 Farnesyltransferase Inhibitors as Anticancer Agents --
18 Targeting Oncogenic Signaling Pathways in Human Astrocytomas --
19 Targeting Oncogenes in Pediatric Malignancies --
20 Inhibiting Signal Transduction as an Approach to Radiosensitizing Tumor Cells --
21 Oncogenes as Targets for Cancer Vaccines --
22 Bcl-2 Antisense Oligonucleotides Therapy for Cancer: Targeting the Mitochondria.

In recent years an entirely new category of anticancer agents has entered the clinic. This class of drugs, the frontrunners of which are Herceptin and Gleevec, are no longer a product of the intuitive and largely empirical explorations that brought about traditional anticancer treatments like chemotherapy. Rather, these new agents have emerged directly from molecular analysis of various cancer-causing genes (oncogenes). In Oncogene-Directed Therapies, prominent investigators and clinicians, several of them pioneers in the field, summarize what is known about oncogenes and oncogenesis-in a balanced blend of fundamental science, basic research, experimental therapeutics, and early clinical experience-and describe how that knowledge can be used to treat the disease. The contributors explain how, why, and under what conditions certain proteins acquire the ability to transform eukaryotic cells, and detail the crucial biological consequences of this oncogenic transformation, particularly for cellular mitogenesis, survival, differentiation, migration, proteolysis, or angiogenic competence. Their articles thoroughly explicate the premises, principles, techniques, and approaches to oncogene targeting in various types of human cancer by using signal transduction inhibitors, immunological targeting methods, and antisense gene therapy. Also included is a review of the results of preclinical and clinical testing of some of today's most advanced therapeutic agents. Unique in perspective and comprehensive in its coverage, Oncogene-Directed Therapies not only integrates for all those engaged in-or simply interested in the cutting-edge of-"the war on cancer" the many remarkable recent achievements in our molecular understanding and treatment of these diseases, but also clarifies what directions future research might optimally take, as well as what significant accomplishments might lie ahead.

There are no comments on this title.

to post a comment.